Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases. Inipharm's lead programs are focused on the highly validated genetic target, HSD17B13. Extensive, consistent evidence that genetic variants in expression of HSD17B13 are associated with significantly lower rates and severity of multiple liver diseases. Building on these novel insights into the biologic activity of HSD17B13, Inipharm is advancing a pipeline of small-molecule therapies that target the activity of this protein.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/12/20 | $35,000,000 | Series A |
5AM Ventures Frazier Healthcare Partners Jubilant Biosys Limited Wu Capital | undisclosed |
